Publications

Archer Goode E, Orozco‑Moreno M, Hodgson K, Nabilah A, Murali M, Peng Z, Merx J, Rossing E, Pijnenborg JFA, Boltje TJ, Wang N, Elliott DJ & Munkley J. Sialylation Inhibition Can Partially Revert Acquired Resistance to Enzalutamide in Prostate Cancer Cells. Cancers 2024 16(17), 2953 https://doi.org/10.3390/cancers16172953

Hodgson K, Orozco‑Moreno M, Archer Goode E, Fisher M, Garnham R, Beatson R....Drake RR, Wang N & Munkley J. Sialic acid blockade inhibits the metastatic spread of prostate cancer to bone. eBioMedicine 2024 104:105163 https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(24)00198-1/fulltext

Orozco‑Moreno M, Visser E, Hodgson K, Hipgrave Ederveen AL, Bastian K, Archer Goode E... Boltje TJ & Munkley J. Targeting aberrant sialylation and fucosylation in prostate cancer cells using potent metabolic inhibitors. Glycobiology 2023 cwad085 https://doi.org/10.1093/glycob/cwad085

Hodgson H, Orozco‑Moreno M, Scott E, Garnham R.....Elliott DJ & Munkley J. The role of GCNT1 mediated O‑glycosylation in aggressive prostate cancer. Scientific Reports 2023 13, Article number: 17031. https://rdcu.be/dn8nu

Scott E, Archer Goode E, Garnham R... Drake RR & Munkley J. ST6GAL1-mediated aberrant sialylation promotes prostate cancer progression. Journal of Pathology 2023. doi: 10.1002/path.6152 https://pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/path.6152

Scott E, Hodgson K...Schumann B & Munkley J. Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth. Oncogene 2023, 42, 926–937. https://www.nature.com/articles/s41388-023-02604-x

Archer Goode E, Wang N & Munkley J. Prostate cancer bone metastases biology and clinical management. Oncology Letters 2023. https://doi.org/10.3892/ol.2023.13749

Munkley, J. Aberrant Sialylation in Cancer: Therapeutic Opportunities. Cancers 2022,

14(17):4248. https://www.mdpi.com/2072-6694/14/17/4248

Bastian K, Scott E, Elliott DJ, Munkley J. Fut8 alpha-(1,6)-fucosyltransferase in cancer. International Journal of Molecular Sciences 2021, 22(1), 1-22. https://www.mdpi.com/1422-0067/22/1/455

Scott E, Elliott DJ, Munkley J. Tumour-associated glycans: A route to boost immunotherapy?. Clinica Chimica Acta 2020, 502, 167-173. https://www.sciencedirect.com/science/article/abs/pii/S0009898119321849?via%3Dihub

Garnham R, Scott E, Livermore KE, Munkley J. ST6GAL1: A key player in cancer (Review). Oncology Letters 2019, 18(2), 983-989. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607188/

Munkley J, Li L, Krishnan SRG, Hysenaj G, Scott E, Dalgliesh C, Oo HZ, Maia TM, Cheung K, Ehrmann I, Livermore KE, Zielinska H, Thompson O, Knight B, McCullagh P, McGrath J, Crundwell M, Harries LW, Daugaard M, Cockell S, Barbosa-Morais NL, Oltean S, Elliott DJ. Androgen-regulated transcription of ESRP2 drives alternative splicing patterns in prostate cancer. eLife 2019, 8, e47678. https://elifesciences.org/articles/47678

Scott E, Munkley J. Glycans as Biomarkers in Prostate Cancer. International Journal of Molecular Sciences 2019, 20(6), 1389. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470778/

Munkley J, Vodak D, Livermore KE, James K, Wilson BT, Knight B, Mccullagh P, Mcgrath J, Crundwell M, Harries LW, Leung HY, Robson CN, Mills IG, Rajan P, Elliott DJ. Glycosylation is an Androgen-Regulated Process Essential for Prostate Cancer Cell Viability. eBioMedicine 2016, 8, 103-116. https://www.sciencedirect.com/science/article/pii/S2352396416301530

Munkley J. Glycosylation is a global target for androgen control in prostate cancer cells. Endocrine Related Cancer 2017, 24, R49-R64. https://erc.bioscientifica.com/view/journals/erc/24/3/R49.xml

Munkley J, Elliott DJ. Hallmarks of glycosylation in cancer. Oncotarget 2016, 7, 35478-35489. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085245/

Munkley J, Mills IG, Elliott DJ. The role of glycans in the development and progression of prostate cancer. Nature Reviews Urology 2016, 13(6), 324-333. https://www.nature.com/articles/nrurol.2016.65

Publications

Patents

This website uses cookies.